Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacoeconomic Comparison of Long-Acting vs Short-Acting Biologics in Moderate-to-Severe Plaque Psoriasis
ChiCTR2600129460Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of ustekinumab and secukinumab in plaque psoriasis (2 arms), sponsored by The First Affiliated Hospital of Guangxi Medical University. Primary endpoint: Incremental Cost-Utility Ratio (ICUR). Planned start Aug 2026; status: not yet recruiting.
02
Drugs
ustekinumabsecukinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on ChiCTR2600129460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600129460.